The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia
Open accessAbstract
Objective: To examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) trial. Study design: This was a secondary analysis of data from the ASPRE trial. In this multicenter-study women with singleton pregnancies had screening by means of an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine-artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor) at 11-13 weeks’ gestation. Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg per day) vs. placebo from 11 to 14 until 36 weeks’ gestation. Preterm preeclampsia with delivery at <37 weeks’ gestation, which was the primary outcome, occurred in 1.6% (13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74). The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic-regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of <90% and >90%, after adjustment for the estimated risk of preterm preeclampsia at screening and the participating center. The choice of cut-off of 90% was based on an exploratory analysis of the treatment effect. Logistic regression analysis was used to investigate predictors of compliance >90% among maternal characteristics and medical history. Results: Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥ 90%, in 8/243 (3.3%) of participants in the aspirin group with compliance <90%, in 22/588 (3.7%) of participants in the placebo group with compliance ≥ 90%, and in 13/234 (5.6%) of participants in the placebo group with compliance <90%. The odds ratio in the aspirin group for preterm preeclampsia was 0.24 (95% confidence interval, 0.09 to 0.65) for compliance >90% and 0.59 (95% confidence interval, 0.23 to 1.53) for compliance <90%. Compliance was positively associated with family history of preeclampsia and negatively associated with smoking, maternal age <25 years, Afro-Caribbean and South Asian racial origin, and history of preeclampsia in a previous pregnancy. Conclusions: The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Self-citationA meta-analysis of the association between adherence to drug therapy and mortality
Simpson, S. H., Eurich, D. T., Majumdar, S. R., Padwal, R. S., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2006) · BMJ · doi:10.1136/bmj.38875.675486.55 · Cited by 1,353
Roberge, S., Nicolaides, K., Demers, S., Hyett, J., Chaillet, N., & Bujold, E. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.09.076 · Cited by 679
Self-citationUterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia
Plasencia, W., Maiz, N., Bonino, S., Kaihura, C., & Nicolaides, K. H. (2007) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.5157 · Cited by 425
Self-citationShingler, S. L., Bennett, B. M., Cramer, J. A., Towse, A., Twelves, C., & Lloyd, A. J. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.952715 · Cited by 55
Cited by
Poon, L. C., Shennan, A., Hyett, J. A., Kapur, A., Hadar, E., Divakar, H., McAuliffe, F., da Silva Costa, F., von Dadelszen, P., McIntyre, H. D., et al. (2019) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12802 · Cited by 1,238
Self-citationAspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis
Roberge, S., Bujold, E., & Nicolaides, K. H. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.561 · Cited by 628
Self-citationScreening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation
Tan, M. Y., Syngelaki, A., Poon, L. C., Rolnik, D. L., O'Gorman, N., Delgado, J. L., Akolekar, R., Konstantinidou, L., Tsavdaridou, M., Galeva, S., et al. (2018) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.19112 · Cited by 438
Self-citationPrevention of preeclampsia with aspirin
Rolnik, D. L., Nicolaides, K. H., & Poon, L. C. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.045 · Cited by 390
Self-citationTan, M. Y., Wright, D., Syngelaki, A., Akolekar, R., Cicero, S., Janga, D., Singh, M., Greco, E., Wright, A., Maclagan, K., et al. (2018) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.19039 · Cited by 385
Self-citation
Metadata
- Authors
- Wright, D., Poon, L. C., Rolnik, D. L., Syngelaki, A., Delgado, J. L., Vojtassakova, D., de Alvarado, M., Kapeti, E., Rehal, A., Pazos, A., Carbone, I. F., Dutemeyer, V., Plasencia, W., Papantoniou, N., & Nicolaides, K. H.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 217
- Issue
- 6
- Pages
- 685.e1-685.e5
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2750924434
- Cited by
- 169
- References
- 5
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. https://app.cochat.ai/papers/10.1016/j.ajog.2017.08.110
- The paper
- Wright, D., Poon, L. C., Rolnik, D. L., Syngelaki, A., Delgado, J. L., Vojtassakova, D., de Alvarado, M., Kapeti, E., Rehal, A., Pazos, A., Carbone, I. F., Dutemeyer, V., Plasencia, W., Papantoniou, N., & Nicolaides, K. H. (2017). Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2017.08.110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.